• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Neuraxis, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    64134X201

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (continued on the following pages)

     

     

     

     
     

     

    CUSIP No. 64134X201 13G  

     

    1

    NAMES OF REPORTING PERSONS

     

    Brian P. Hannasch

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ☐    

     

    (b) ☐    

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    695,753 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    695,753 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    695,753 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐

     

    N/A

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    10.2% (1)(2)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

     

    (1) Includes 12,852 shares of common stock of Neuraxis, Inc. (the “Issuer”) issuable upon the exercise of currently exercisable warrants held by Mr. Hannasch (the “Warrant Shares”).
       
    (2) Based on 6,841,621 outstanding shares of the Issuer’s common stock as of August 8, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024, plus the Warrant Shares.

     

     
     

     

    Item 1.

     

      (a) Name of Issuer

     

    Neuraxis, Inc. (the “Issuer”)

     

      (b) Address of Issuer’s Principal Executive Offices

     

    11611 N. Meridian Street, Suite 330

    Carmel, Indiana 46032

     

    Item 2.

     

      (a) Name of Person Filing

     

    Brian P. Hannasch

     

      (b) Address of Principal Business Office or, if none, Residence

     

    8815 W. State Road 46

    Columbus, Indiana 47201

     

      (c) Citizenship

     

    United States

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

      (e) CUSIP Number

     

    64134X201

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act;
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act;
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act;
           
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

     
     

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned

     

    695,753 shares (1)

     

      (b) Percent of Class

     

    10.2% (1)(2)

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote

     

    695,753 shares (1)

     

      (ii) Shared power to vote or to direct the vote

     

    0 shares

     

      (iii) Sole power to dispose or to direct the disposition of

     

    695,753 shares (1)

     

      (iv) Shared power to dispose or to direct the disposition of

     

    0 shares

     

     

    (1) Includes 12,852 shares of Common Stock issuable upon the exercise of currently exercisable warrants held by Mr. Hannasch (the “Warrant Shares”).
       
    (2) Based on 6,841,621 outstanding shares of the Common Stock as of August 8, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024, plus the Warrant Shares.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:

    October 8, 2024

     
         
    By: /s/ Brian P. Hannasch  
      Brian P. Hannasch  

     

     

    Get the next $NRXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

      CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share. The gross proceeds from the offering are approximately $5.0 million, before deducting placement agent fees and other offering expenses. "This financing, along with the recent FDA clearance expanding indications for IB-Stim treatment of Pediatric Functional Abdominal Pain (FAP), marks a

      5/22/25 1:03:01 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis Announces $5.0 Million Registered Direct Offering

      CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules. The offering is expected to close on or about May 22, 2025, subject to the satisfaction of customary closing conditions. Craig-Hallum Capital Group is acting as the exclusive place

      5/21/25 7:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

      •   Significantly expands IB-Stim's total addressable market •   Clearance covers patients aged 8–21 •   Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for IB-Stim™ for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years. This clearance is t

      5/20/25 8:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

      4 - Neuraxis, INC (0001933567) (Issuer)

      4/23/25 4:38:50 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Aharon Gil

      3 - Neuraxis, INC (0001933567) (Issuer)

      11/26/24 3:57:02 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Ferge Kristin A was granted 1,183 shares (SEC Form 4)

      4 - Neuraxis, INC (0001933567) (Issuer)

      7/2/24 3:18:16 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    See more
    • NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

      CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

      1/31/24 9:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Financials

    Live finance-specific insights

    See more

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NRXS
    SEC Filings

    See more
    • NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

      CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.Cash balance was $2.0 million as

      5/12/25 8:15:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

      CARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before market open. The Company has scheduled a conference call for the same day, Monday, May 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Monday, May 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, which is availab

      5/5/25 9:00:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

      CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024. 4Q24 Financial highlights Revenues increased 43% to $761 thousand in 4Q24 compared to $531 thousand in 4Q23.Operating loss improved by 10% compared to the fourth quarter of 2023.Cash balance was $3.7 million as of December 31, 2024. Recent Operational Highlights Expanded total covered lives to approximately 51 million compared to 4 million a

      3/20/25 8:15:00 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by Neuraxis Inc.

      SC 13D - Neuraxis, INC (0001933567) (Subject)

      12/2/24 11:53:07 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Neuraxis Inc.

      SC 13G - Neuraxis, INC (0001933567) (Subject)

      12/2/24 9:57:28 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

      SC 13G/A - Neuraxis, INC (0001933567) (Subject)

      10/8/24 7:30:11 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 8-K filed by Neuraxis Inc.

      8-K - Neuraxis, INC (0001933567) (Filer)

      5/22/25 6:45:22 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Neuraxis Inc.

      424B5 - Neuraxis, INC (0001933567) (Filer)

      5/22/25 6:30:45 AM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Neuraxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Neuraxis, INC (0001933567) (Filer)

      5/21/25 5:25:26 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

      4 - Neuraxis, INC (0001933567) (Issuer)

      4/23/25 4:38:50 PM ET
      $NRXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care